Exciting News from the MyMeta Force Team!
June 1, 2023 | BALTIMORE – Complete Omics’ Clinical Metablomics team are overjoyed to announce that Dr. Liang Zhao, an esteemed expert in metabolomics, proteomics, and lipidomics, with a profound focus on cancer metabolism and immuno-metabolism, has joined our MyMeta Force team as the leader. Dr. Zhao’s pioneering research involves the sophisticated application of mass spectrometry-based metabolomics and proteomics, alongside integrating molecular biology and bioinformatics, to unravel the biomedical significance of metabolites and proteins. His dedication to translating omics findings into clinical applications is notable, aiming at the development of innovative biomarkers, AI-enhanced diagnostic panels, and novel therapeutic strategies for cancer treatment.
Exciting Feature: Complete Omics and Our Founder Qing Wang Shine on The Scientist’s Channel!
July 18, 2021 | BALTIMORE – Complete Omics team is thrilled to announce an extraordinary milestone for Complete Omics Inc. The Scientist’s Channel, renowned for spotlighting the trailblazers at the forefront of scientific inquiry and innovation, has featured our esteemed founder, Qing Wang, in a compelling showcase that highlights the groundbreaking work we are doing here at Complete Omics.
Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy.
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
Happy Holidays from Complete Omics!
December 23, 2021 | BALTIMORE – Dear Team Members and Friends: 2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and patient care by advancing our multi-omics molecular diagnostic pipelines even further. In the year of 2021, over 80 new research papers featuring Complete Omics’ technologies and platforms have been published. Since 2021 summer, Complete Omics started to offer cutting-edge multi-omics research services backed up by our top profile publications and patents. Now we are thrilled to work with over 30 pharmaceutical corporations and over 50 research labs worldwide to implement our Complete360® multi-omics molecular diagnostic pipeline and our Valid-NEOTM companion diagnostics pipeline. Hundreds of novel biomarkers and dozens of new drug targets are identified and quantified by us, and numerous treatment approaches are being developed based on our discoveries. We expect massive new features to be added on to our platforms over the next few years, and many exciting new discoveries ahead from ourselves and from the collaborations with scientists throughout the world. Please follow our company’s progress or contact us at info@completeomics.com to learn more about how we can advance your research and patient care. All of us at Complete Omics wish you a Merry Christmas and Happy New Year of 2022!
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
